1 Category: Infectious Disease

- 2
- 3 **TITLE:**

4 EVALUATION OF THE ABBOTT SARS-COV-2 IG-G ASSAY.

5

6 Authors:

- 7 Lau CS¹, Hoo SP¹, Liang YL¹, Aw TC^{1,2,3*}
- 8 1. Department of Laboratory Medicine, Changi General Hospital, Singapore.
- 9 2. Department of Medicine, National University of Singapore, Singapore.
- 10 3. Academic Pathology Program, Duke-NUS Medical School, Singapore.
- 11

12 * Corresponding Author

- 13 Address: Department of Laboratory Medicine, CHANGI GENERAL
- 14 HOSPITAL, 2 SIMEI STREET 3, SINGAPORE 529889
- 15 **E-mail:** <u>tarchoon@gmail.com</u>
- 16 **Phone: +**65 68504927
- 17 **Fax: +**65 64269507
- 18
- 19 **Disclosure:** All authors have nothing to disclose.

21 ABBREVIATIONS

- 22 SARS-CoV-2 Novel severe acute respiratory syndrome coronavirus 2
- 23 COVID-19 Coronavirus disease 2019
- 24 CDC Centers for Disease Control and Prevention
- 25 RCPA Royal College of Pathologists of Australasia
- 26 RF Rheumatoid factor
- 27 PCR Polymerase chain reaction
- 28 COI Cut-off index
- 29 CV Inter-assay precision
- 30 CAP College of American Pathologists
- 31 PPA Positive percentage agreement
- 32 POS Post positive PCR
- 33 NPA Negative percentage agreement
- 34 FDA Food and Drug Administration

35

- 37
- 38
- 39
- 40
- 41

42 ABSTRACT

Introduction: Antibodies to the novel severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) can increase as soon as 10-13 days after infection. We describe our
evaluation of the Abbott SARS-CoV-2 IgG assay on the Architect immunoassay analyser.

46

47 Methods: We assessed the precision, sensitivity, and specificity of the Abbott SARS-CoV-2 48 lgG assay in samples from polymerase chain reaction (PCR) positive patients and healthy 49 healthcare workers. The manufacturer cut-off index (COI) of 1.4 was adopted to identify 50 positive results. We examined the assay cross-reactivity with other viral antibodies 51 (influenza/dengue/hepatitis C/hepatitis B) and rheumatoid factor (RF). The sample 52 throughput of the Abbott assay was also assessed.

53

Results: The Abbott assay showed excellent precision, with a CV of 3.4% for the negative control (COI = 0.06) and 1.6% for a high positive serum sample (COI = 8.6). Residual serum was available from 57 inpatients not initially suspected of having COVID-19, 29 of whom tested positive for SARS-CoV-2 IgG. The Abbott assay has a sensitivity of 90.9-100% when tested in 54 subjects \geq 14 days post PCR positive, and a specificity of 100% (N = 358). There was no cross-reactivity with other viral antibodies (influenza/dengue/hepatitis C/hepatitis B) and RF. The Architect Abbott assay has a throughput of 100 samples in 70 minutes.

61

62 Conclusion: The Abbott SARS-CoV-2 IgG assay shows excellent performance that is well 63 within FDA and CDC guidelines when testing patients ≥14 days POS with little cross-64 reactivity from other viral antibodies. There is some evidence that SARS-CoV-2 IgG 65 develops early in the disease process.

67 **IMPACT STATEMENT**

68	With the current SARS-CoV-2 pandemic still ongoing, laboratories are hard pressed to
69	introduce SARS-CoV-2 antibody testing to help as an indirect marker for infection to identify
70	patients with prior infection/exposure. The Abbott SARS-CoV-2 IgG assay has excellent
71	performance with good precision, specificity, and sensitivity ≥14 days after a positive SARS-
72	CoV-2 PCR test, with a competitive throughput of 100 samples in 70 minutes. It shows no
73	cross-reactivity with other viral antibodies (influenza/dengue/hepatitis B/hepatitis C) and
74	rheumatoid factor. We have also found evidence of early antibody development in some
75	patients before they tested positive on the SARS-CoV-2 PCR test.
76	
77	
78	
79	
80	
81	
82	
83	
84	
85	
86	
87	
88	
89	

90 INTRODUCTION

91 The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to mild 92 or moderate coronavirus disease 2019 (COVID-19) with cough, fever, malaise, myalgias, 93 gastrointestinal symptoms and anosmia (1), or a severe disease with acute respiratory 94 distress syndrome (2). The need for the serological diagnosis of SARS-CoV-2 has become 95 acute. The Centers for Disease Control and Prevention (CDC) (3) and the Royal College of 96 Pathologists of Australasia (RCPA) (4) stipulate that only viral testing (nucleic acid or 97 antigen) is the standard test to diagnose acute infection. However, some studies (5, 6) show 98 that the SARS-CoV-2 antibodies can increase as soon as 10-13 days after infection. 99 Antibody tests can act as an indirect marker for infection and help identify patients with prior 100 infection/exposure who have developed an immune response (7). Abbott has developed a 101 SARS-CoV-2 IgG assay for use with its Architect immunoassay analysers for the rapid 102 testing of large numbers of samples. We describe our evaluation of the Abbott SARS-CoV-2 103 IgG assay.

104

105 MATERIALS AND METHODS

106 Patient cohorts:

107 Residual serum from cases with suspected or confirmed SARS-CoV-2 infection from April to 108 May 2020 were recruited. Samples testing positive for dengue fever/Anti-HCV/HBsAg/anti-109 HBc IgM and rheumatoid factor (RF) were used to check for cross-reactivity in the SARS-110 CoV-2 IgG assay. Volunteers (laboratory staff and frontline healthcare workers) from our 111 hospital also provided serum samples as control subjects. All samples were collected in 112 plain serum tubes.

113 Instrumentation and analysis:

114 For SARS-CoV-2 polymerase chain reaction (PCR) testing, our hospital molecular laboratory 115 employs a duplex real-time PCR that targets the N and E genes using a Qiagen EZ1 116 extraction system and Rotor Gene Q amplification system. The Abbott SARS-CoV-2 IgG 117 assay is a qualitative chemiluminescent microparticle immunoassay used for the detection of 118 IgG antibodies to SARS-CoV-2 (undisclosed epitope on the viral nucleocapsid) in human 119 serum/plasma on the ARCHITECT i2000 System. The sample, SARS-CoV-2 antigen coated 120 paramagnetic microparticles, and assay diluent are combined and incubated. Thereafter, 121 anti-human IgG acridinium-labelled conjugate is added to create a reaction mixture. 122 Following the addition of pre-trigger and trigger solutions, the resulting chemiluminescent 123 reaction is directly proportional to the amount of IgG antibodies. When compared to the 124 mean chemiluminescent signal of a calibrator, an IgG index is derived with a reported cut-off 125 index (COI) of 1.4. The assay has a stated inter-assay precision (CV) of 5.9% and 1.2% for 126 negative and positive controls at a mean COI of 0.04 and 3.53. The reported assay 127 specificity is 99.6% and sensitivity of 100% for samples ≥14 days post symptom onset. To 128 prevent potential interactions, maintenance has to be performed to and following the 129 batching of 50 SARS-CoV-2 IgG samples (Abbott SARS-CoV-2 IgG assay package insert, 130 H07891R02, April 2020).

Statistical analyses were performed using MedCalc software v19.3.1 (MedCalc, Ostend,
Belgium). As this work was part of routine evaluation of new diagnostic assays, it was
deemed exempt by our institutional review board.

134

135 **RESULTS**

For precision analysis, 5 pools (including negative and positive Abbott controls, and 3 positive serum samples over a range of COI values) were run 5 times daily over 5 days as per the CLSI EP15-A3 protocol (8). The Abbott assay showed excellent precision, with a CV

of 3.4% (negative control, COI = 0.06) and 1.6% (serum sample, COI = 8.6) (Supplemental
Table 1).

For sensitivity testing [positive percentage agreement, (PPA)], we used 338 PCR positive COVID-19 cases; cases with unknown PCR status (N = 5) and PCR negative cases (N = 10) were excluded. 57 of these cases were residual samples from inpatients who were not initially suspected of having COVID-19 but subsequently tested positive for SARS-CoV-2 PCR. Notably, 29 of these 57 samples were positive for IgG prior to having a positive PCR test. Of the remaining 266 samples, the PPA increased to 90.9% after 14 days post positive PCR (POS) and 100% by 21 days POS (see Table 1).

148

149 < TABLE 1 >

150

151 For specificity testing [negative percentage agreement (NPA)], we included 294 samples 152 from healthcare workers, 46 samples positive for dengue, 3 samples positive for Anti-HCV, 8 153 samples positive for HBsAg, 2 samples positive for anti-HBc IgM, and 5 RF positive 154 samples. All these samples were from subjects with no suspicion for COVID-19. None of 155 these cases tested positive, yielding a total specificity of 100% (95% CI 98.98 to 100.00) 156 (See Table 2). The sero-negativity of our healthcare workers also underscores the adequacy 157 of our personal protective equipment measures. However, they remain at risk for future 158 COVID-19 infections, and continued safety precautions should still be enforced. We also 159 analysed for any potential cross-reactivity from antibodies consequent to recent influenza 160 vaccination (239 staff had received their influenza vaccination 4 weeks prior to testing). 161 None of these cases (dengue, recent influenza vaccination cases, or positive Anti-HCV, 162 HBsAg, anti-HBc IgM and RF) tested positive for SARS-CoV-2 IgG.

163

164 <TABLE 2>

165

The throughput of the Architect Abbott assay was examined. The Architect was able to analyse 100 specimens for SARS-CoV-2 IgG in 1 hour 9 minutes and took 2 hours 9 minutes to analyse 250 specimens.

169

170 **DISCUSSION**

171 The Abbott SARS-CoV-2 IgG assay shows excellent performance, with a CV of 3.4% and 172 1.9% for the negative and positive calibrators. The diagnostic sensitivity of this assay is 90.9-173 100% \geq 14 days POS, with a specificity of 100%. This is in close agreement with the 174 manufacturer's specifications. Our results are also in keeping with other studies (9-12) that 175 have evaluated the Abbott SARS-CoV-2 IgG assay, where the sensitivity/PPA increases to 176 >90% after 14 days post symptom onset. The US CDC and the Food and Drug 177 Administration (FDA) have stipulated a sensitivity of 90% and specificity of 95% for an 178 acceptable SARS-CoV-2 serology test (13, 14). The Abbott assay easily falls within these 179 requirements. Furthermore, the Abbott assay has an acceptable throughput, which is 180 comparable to other SARS-CoV-2 immunoassays. In the latest revision of the package insert 181 (Abbott SARS-CoV-2 IgG package insert, H70891R03, May 2020), it is heartening to note 182 that the requirement for batch analysis and maintenance pre- and post-testing has been 183 removed.

In our study we have used days POS to categorize our population. Using the onset of patient symptoms as a criterion for SARS-CoV-2 classification will result in the exclusion of asymptomatic patients (15, 16). Using days POS mitigates against this pitfall. We also found 29 patient samples that tested positive for SARS-CoV-2 IgG before a positive PCR test. This underscores the fact that SARS-CoV-2 antibody development may occur earlier than expected in some cases. Our study also confirms that the assay remains specific even in patients with previous dengue infection, recent influenza vaccination, or in the presence of

191 Anti-HCV, HBsAg, anti-HBc IgM and RF. A recent report (17) found that SARS-CoV-2 192 infection may cause false-positive dengue antibody results. It is noteworthy that positive 193 dengue serology in 46 patients did not cause a false positive SARS-CoV-2 IgG. Other 194 evaluations of the Abbott assay also demonstrate little cross-reactivity in patients with 195 previous viral infections and haemodialysis (9). Finally, we have also provided data on the 196 sample throughput of the Abbott assay. A limitation of our study is that it is a single centre 197 study, and we do not have the sero-prevalence of SARS-CoV-2 in our community 198 population. In addition, we only had few samples for cases before and after 0-<7 days POS. 199 Further studies on larger populations would be desirable.

200

201 Conclusion

Overall, our results show that the Abbott SARS-CoV-2 IgG assay has excellent performance and is highly comparable both with the manufacturer's information and other published studies. We look forward to larger studies over longer periods of time to further evaluate the use of serological assays in the management of COVID-19.

206

207

208 References

- (1) Gandhi RT, Lynch JB, Del Rio C. Mild or Moderate Covid-19. [Epub ahead of print] N
 Engl J Med 24 April, 2020 as Doi: 10.1056/NEJMcp2009249.
- (2) Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. [Epub ahead of print] N Engl J Med
 15 May, 2020 as Doi: 10.1056/NEJMcp2009575.
- (3) Centers for Disease Control and Prevention. Evaluating and Testing Persons for
 Coronavirus Disease 2019 (COVID-19). https://www.cdc.gov/coronavirus/2019 ncov/hcp/clinical-criteria.html. (2020, Accessed 22 May 2020).
- 216 (4) The Royal College of Pathologists of Australia. Position Statement, COVID19 IgG/IgM
- 217 Rapid POCT Tests. https://www.rcpa.edu.au/getattachment/bf9c7996-6467-44e6-81f2-

218 e2e0cd71a4c7/COVID19-IgG-IgM-RAPID-POCT-TESTS.aspx. (2020, Accessed 22 May

219 2020).

- (5) Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W, et al. Evaluation of Nucleocapsid and Spike
 Protein-based ELISAs for 2 detecting antibodies against SARS-CoV2. [Epub ahead of
 print] J Clin Microbiol 30 March, 2020 as Doi: 10.1128/JCM.00461-20.
- (6) Long Q, Deng J, Chen J, Hu J, Liu B, Liao P, Lin Y, et al. Antibody responses to SARS-
- CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical
 practice. [Preprint] medRxiv 20 March, 2020 as Doi:
 https://doi.org/10.1101/2020.03.18.20038018.
- (7) U.S. Food and Drug Administration. Important Information on the Use of Serological
 (Antibody) Tests for COVID-19 Letter to Health Care Providers.
 <u>https://www.fda.gov/medical-devices/letters-health-care-providers/important-information-</u>
- use-serological-antibody-tests-covid-19-letter-health-care-providers. (2020, Accessed 22
 May 2020).
- (8) Clinical and Laboratory Standard Institute (CLSI). User Verification of Precision and
 Estimation of Bias; Approved Guideline-Third Edition, CLSI document EP15-A3. PA
 Wayne PA:CLSI 2014.
- (9) Public Health England. Evaluation of the Abbott SARS-CoV-2 IgG for the detection of
 anti-SARSCoV-2 antibodies.
- 237 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment
- 238 <u>data/file/887221/PHE Evaluation of Abbott SARS CoV 2 lgG.pdf</u>. (2020, Accessed
 239 26 May 2020).
- (10) Tang MS, Hock KG, Logsdon NM, Hayes JE, Gronowski AM, Anderson NW, et al.
 Clinical Performance of Two SARS-CoV-2 Serologic Assays. [Epub ahead of print] Clin
 Chem 13 May, 2020 as Doi: 10.1093/clinchem/hvaa120.
- (11) Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody Responses to SARSCoV-2 in Patients of Novel Coronavirus Disease 2019. [Epub ahead of print] Clin Infect
 Dis 28 March, 2020 as Doi: 10.1093/cid/ciaa344.

246	(12) Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, et al.
247	Performance Characteristics of the Abbott Architect 1 SARS-CoV-2 IgG Assay and
248	Seroprevalence in Boise, Idaho. [Epub ahead of print] J Clin Microbiol 7 May, 2020 as
249	Doi: 10.1128/JCM.00941-20.

- 250 (13) Centers for Disease Control and Prevention. Interim Guidelines for COVID-19
- 251 Antibody Testing. <u>https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-</u>
- 252 <u>tests-guidelines.html (2020</u>, accessed 8 June 2020).
- 253 (14) US Food and Drug Administration. EUA Authorized Serology Test Performance.
- 254 https://www.fda.gov/medical-devices/emergency-situations-medical-devices/eua-

255 <u>authorized-serology-test-performance (2020</u>, accessed 29 May 2020).

- (15) Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic
 proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond
- Princess cruise ship, Yokohama, Japan, 2020. [Epub ahead of print] Euro Surveill 12
 March, 2020 as Doi: 10.2807/1560-7917.ES.2020.25.10.2000180.
- (16) Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic Transmission
 of SARS-CoV-2 Singapore, January 23–March 16, 2020. MMWR Morb Mortal Wkly
 Rep 2020; 69: 411–5.
- 263 (17) Yan G, Lee CK, Lam L, Yan B, Chua YX, Lim A, et al. Covert COVID-19 and false-
- 264 positive dengue serology in Singapore. [Epub ahead of print] Lancet 4 March, 2020 as
- 265 Doi: https://doi.org/10.1016/S1473-3099(20)30158-4.
- 266
- 267
- 268
- 269
- 270

- Table 1: Abbott assay sensitivity (positive percentage agreement) by days post
- 276 positive PCR.

Days POS	Ν	IgG positive	IgG negative	PPA (%)	95% CI
0-<7	155	76	79	49.03	40.93 to 57.18
7-<14	57	43	14	75.44	62.24 to 85.87
14-<21	22	20	2	90.91	70.84 to 98.88
≥21	32	32	0	100.00	89.11 to 100.00

- 295
- 296
- 297
- 298

Table 2: Abbott assay interference analysis and specificity (negative percentage

300 agreement).

	Ν	Abbott negative	Abbott positive
Healthcare workers	294	294	0
Dengue fever	46	46	0
Anti-HCV	3	3	0
HBsAg	8	8	0
Anti-HBc IgM	2	2	0
RF positive	5	5	0
Total	358	358	0
Abbott NPA	Abbott NPA 100% (95% CI 98.98 to 100.00)		